Sun Pharmaceutical Industries Limited
National Stock Exchange of IndiaTotal Valuation
Sun Pharmaceutical Industries Limited carries a market capitalization of 4.29T, placing it among publicly traded companies globally. Its enterprise value stands at 4.01T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.29T |
| Enterprise Value | 4.01T |
Valuation Ratios
Sun Pharmaceutical Industries Limited trades at a trailing price-to-earnings ratio of 38.70.
| PE Ratio | 38.70 |
| PS Ratio | 7.53 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sun Pharmaceutical Industries Limited trades at an EV/EBITDA multiple of 31.16 and an EV/FCF ratio of 2,127.67. The EV/Sales ratio of 7.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 31.16 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.53 |
| EV / EBITDA | 31.16 |
| EV / EBIT | 31.16 |
| EV / FCF | 2,127.67 |
Financial Position
Sun Pharmaceutical Industries Limited maintains a current ratio of 5.56, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.97, indicating elevated leverage, while an interest coverage ratio of 52.65 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.56 |
| Quick Ratio | 1.03 |
| Debt / Equity | 6.97 |
| Debt / EBITDA | N/A |
| Interest Coverage | 52.65 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 275.43 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Sun Pharmaceutical Industries Limited has paid 30.90B in income taxes, reflecting an effective tax rate of 22.89.
| Income Tax | 30.90B |
| Effective Tax Rate | 22.89 |
Stock Price Statistics
Sun Pharmaceutical Industries Limited's stock has gained approximately 7.25637% over the past 52 weeks. The 50-day moving average sits at 1,773.70, while the 200-day moving average is 1,722.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | 7.25637% |
| 50-Day Moving Average | 1,773.70 |
| 200-Day Moving Average | 1,722.56 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sun Pharmaceutical Industries Limited generated 533.03B in revenue and converted that into 103.72B in net income, yielding earnings per share of 43.41. EBITDA reached 128.80B, while operating income came in at 128.80B.
| Revenue | 533.03B |
| Gross Profit | 424.16B |
| Operating Income | 128.80B |
| Pretax Income | 135.01B |
| Net Income | 103.72B |
| EBITDA | 128.80B |
| EBIT | 128.80B |
| Earnings Per Share (EPS) | 43.41 |
Margins
Sun Pharmaceutical Industries Limited operates with a gross margin of 79.58, reflecting its pricing power and cost economics. The operating margin of 24.16 and net profit margin of 19.46 provide insight into operational efficiency.
| Gross Margin | 79.58 |
| Operating Margin | 24.16 |
| Pretax Margin | 25.33 |
| Profit Margin | 19.46 |
| EBITDA Margin | 24.16 |
Stock Splits
Sun Pharmaceutical Industries Limited's most recent stock split took place on July 29, 2013 with a 1:2 split ratio.
| Last Split Date | 7/29/2013 |
| Split Ratio | 1:2 |
Scores
Sun Pharmaceutical Industries Limited posts an Altman Z-Score of 32.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 32.10 |